OXBOF (Oxford BioDynamics) Shares Outstanding (EOP): 1,957.58 Mil (As of Sep. 2025)


What is Oxford BioDynamics Shares Outstanding (EOP)?

Oxford BioDynamics OXBOF -33.33% Shares Outstanding (EOP) is 1,957.58 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Oxford BioDynamics's shares outstanding for the quarter that ended in Sep. 2025 was 1,957.58 Mil.

Oxford BioDynamics's quarterly shares outstanding stayed the same from Mar. 2025 (1,957.58 Mil) to Sep. 2025 (1,957.58 Mil).

Oxford BioDynamics's annual shares outstanding increased from Sep. 2024 (311.86 Mil) to Sep. 2025 (1,957.58 Mil). It means Oxford BioDynamics issued new shares from Sep. 2024 to Sep. 2025 .


Oxford BioDynamics  (OTCPK:OXBOF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Oxford BioDynamics Shares Outstanding (EOP) Related Terms


Oxford BioDynamics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Oxford BioDynamics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioDynamics Shares Outstanding (EOP) Chart

Oxford BioDynamics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.56 100.35 202.30 311.86 1,957.58

Oxford BioDynamics Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 202.30 202.30 311.86 1,957.58 1,957.58

OXBOF vs TMO, DHR, IDXX: Shares Outstanding (EOP) Comparison

For the Diagnostics & Research subindustry, Oxford BioDynamics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioDynamics Shares Outstanding (EOP) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's Shares Outstanding (EOP) falls into.



Oxford BioDynamics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 1,957.58 Mil mean?
Oxford BioDynamics (OXBOF) has a Shares Outstanding (EOP) of 1,957.58 Mil as of Sep. 2025. The total shares a company has outstanding, at period-end. View historical data on Oxford BioDynamics and its competitors.
Is Oxford BioDynamics' Shares Outstanding (EOP) too high?
Oxford BioDynamics' current Shares Outstanding (EOP) is 1,957.58 Mil.
How does Oxford BioDynamics' Shares Outstanding (EOP) compare to TMO and DHR?
Oxford BioDynamics' Shares Outstanding (EOP) of 1,957.58 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Diagnostics & Research company?
A good Shares Outstanding (EOP) depends on the Medical Diagnostics & Research industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Oxford BioDynamics and its competitors. Oxford BioDynamics's current Shares Outstanding (EOP) is 1,957.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (OXBOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.00 — trading 96.7% below its estimated fair value. The current Shares Outstanding (EOP) is 1,957.58 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Oxford BioDynamics (OXBOF), the current Shares Outstanding (EOP) is 1,957.58 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oxford BioDynamics Business Description

Other Exchanges OBD:UKLMQ:Germany
Address John Smith Drive, 3140 Rowan Place, Oxford Business Park South, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.